Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sygnis Pharma has completed the acquisition of Spanish company, X-Pol Biotech.
Subscribe to our email newsletter
The annual general meeting held on 17 October 2012, has approved the acquisition of 100% of the shares of X-Pol by way of a capital increase against contribution in kind.
With the acquisition, former shareholders of X-Pol will hold 77.5% of Sygnis shares while the former Sygnis shareholders will be eligible for 22.5% shares of X-Pores.
German-based Sygnis Pharma focuses on research and development of new therapies to treat diseases of the central nervous system while X-Pol Biotech aims at the development of tools and technologies for the DNA amplification and sequencing market.